252 related articles for article (PubMed ID: 21833048)
21. Placebo use in Council of Europe biomedical research instruments.
Zilgalvis P
Sci Eng Ethics; 2004 Jan; 10(1):15-22. PubMed ID: 14986766
[No Abstract] [Full Text] [Related]
22. Time for new rules on human subjects research?
Dresser R
Hastings Cent Rep; 1998; 28(6):23-4. PubMed ID: 9868606
[No Abstract] [Full Text] [Related]
23. Extend the reach of institutional review boards first, then strengthen their depth.
Spike J
Am J Bioeth; 2008 Nov; 8(11):11-2. PubMed ID: 19061097
[No Abstract] [Full Text] [Related]
24. Recruiting human subjects without IRB review/approval.
Maloney DM
Hum Res Rep; 2002 Aug; 17(8):3. PubMed ID: 12731493
[No Abstract] [Full Text] [Related]
25. New guidelines for institutional review boards stress special role.
Maloney DM
Hum Res Rep; 2000 Dec; 15(12):1-2. PubMed ID: 11789516
[No Abstract] [Full Text] [Related]
26. Federal drug agency gets flack about human subjects protections in clinical trials.
Beckman M
J Natl Cancer Inst; 2008 Jan; 100(2):90-1. PubMed ID: 18182612
[No Abstract] [Full Text] [Related]
27. New guidance on reviews by central institutional review boards (IRBs).
Maloney DM
Hum Res Rep; 2005 May; 20(5):1-2. PubMed ID: 16175714
[No Abstract] [Full Text] [Related]
28. Toward protecting the safety of participants in clinical trials.
Califf RM; Morse MA; Wittes J; Goodman SN; Nelson DK; DeMets DL; Iafrate RP; Sugarman J
Control Clin Trials; 2003 Jun; 24(3):256-71. PubMed ID: 12757992
[TBL] [Abstract][Full Text] [Related]
29. Ethical oversight of research in developing countries.
Kass N; Dawson L; Loyo-Berrios NI
IRB; 2003; 25(2):1-10. PubMed ID: 12833901
[No Abstract] [Full Text] [Related]
30. Ethics of private panels comes under scrutiny.
Wadman M
Nature; 1997 May; 387(6632):445. PubMed ID: 9168099
[No Abstract] [Full Text] [Related]
31. The ethics approval process for multisite research studies in Australia: changes sought by the Australian Genomics initiative.
Haas MA; Boughtwood TF; Quinn MC;
Med J Aust; 2019 Nov; 211(10):440-444.e1. PubMed ID: 31734945
[No Abstract] [Full Text] [Related]
32. New federal rule on protecting children as research subjects.
Maloney DM
Hum Res Rep; 2001 Jun; 16(6):3. PubMed ID: 11785526
[No Abstract] [Full Text] [Related]
33. Changing the paradigm: new directions in federal oversight of human research.
Koski G
J Pediatr Gastroenterol Nutr; 2003; 37 Suppl 1():S2-6. PubMed ID: 14685070
[TBL] [Abstract][Full Text] [Related]
34. [Take-over of the risk-benefit by the clinical study subject and its regulation].
Antal J
Orv Hetil; 2005 Jun; 146(26):1399-404. PubMed ID: 16052982
[TBL] [Abstract][Full Text] [Related]
35. The role of controversial research in the IRB's risk/benefit analysis.
Lunstroth J
Am J Bioeth; 2011 May; 11(5):14-6. PubMed ID: 21534141
[No Abstract] [Full Text] [Related]
36. Clinical trials: a medical Catch-22. Researchers, institution boards must take appropriate steps to protect participants.
Serbaroli F
Mod Healthc; 2002 Oct; 32(41):23. PubMed ID: 12415995
[No Abstract] [Full Text] [Related]
37. Are human research subjects safe enough?
Thompson RE
Physician Exec; 2003; 29(4):52-4. PubMed ID: 14650072
[No Abstract] [Full Text] [Related]
38. Comparison of requirements of research ethics committees in 11 European countries for a non-invasive interventional study.
Hearnshaw H
BMJ; 2004 Jan; 328(7432):140-1. PubMed ID: 14726341
[No Abstract] [Full Text] [Related]
39. IRBs and monitoring the safety of clinical trials.
Maloney DM
Hum Res Rep; 2003 Jan; 18(1):3. PubMed ID: 12755095
[No Abstract] [Full Text] [Related]
40. Regulating clinical research: informed consent, privacy, and IRBs.
Hoffman S
Cap Univ Law Rev; 2003; 31(1):71-91. PubMed ID: 15295833
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
